^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Esophageal Adenocarcinoma
    Drug:Cyramza (ramucirumab) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...the guidelines have included the targeted therapy ramucirumab (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma) as a single agent...
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    ...the guidelines have included the targeted therapy ramucirumab (category 1 for EGJ adenocarcinoma; category 2A for esophageal adenocarcinoma) as a single agent or in combination with paclitaxel (preferred) as treatment options for second line or subsequent therapy....Esophageal and Esophagogastric Junction Cancers: Useful in Certain Circumstances…Fluorouracil and irinotecan + ramucirumab (only for adenocarcinoma)...Esophageal and Esophagogastric Junction cancers: Other recommended regimens…Irinotecan and ramucirumab for adenocarcinoma…
    Secondary therapy:
    irinotecan; ; 5-fluorouracil + irinotecan